Klinična imunologija, KOPB: zbornik predavanj - Bolnišnica Golnik

LITERATURA1. King Jr TE: Clinical Advances in the Diagnosis and Therapy of the Interstitial Lung Diseases. Am JRespir Crit Care Med 2005;172:268-279.2. Behr J.: lungenfibroze- Aktuelle Aspekte in Diagnostik und Therapie, UNI_MED 2003, 1-122.3. Mušič E: Prispevek k diagnostiki in zdravljenju difuznih intersticijskih pljučnih bolezni. Zdrav Vestn1994;63: 461-466.4. ATS/ERS: American Thoracic Society/ European Respiratory Society International MultidisciplinaryConsensus classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;165:277-304.5. Mušič E: Klasifikacija, diagnostika in načela zdravljenja difuznih interstcijskih pljučnih bolezni. 46.Tavčarjevi dnevi 2004: 31-43.6. Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curan-Everett D, King TE, Brown KK: CombinedCotikosteroid and Cyclophosphamide therapy Does Not Alter Survival in Idiopathic Pulmonary Fibrosis.Chest 2004;125:2169-2174.7. Raghu G: Idipathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches. EurRespir J 2006;28:463-465.8. Ziegenhagen MW, Müller-Quernheim J: Idiopathische Pulmonale fibrose (IPF): Diagnose,Differenzialdiagnoze, und neue Therapieoptionen. Dtsch Med Wochenschr 2004;129: 494-498.9. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU: The relationship betweenIndividual hisologic features and Disease progression in idiopathic pulmonary Fibrosis. Am J Respir CritCare Med 2002; 166:173-177.84